NASDAQ:PRFX

PainReform - PRFX Stock Forecast, Price & News

$0.50

+0.11 (+29.49%)

(As of 12/9/2022 01:31 PM ET)

Add

Compare

Today's Range: $0.44
▼
$0.55
50-Day Range: $0.38
▼
$0.69
52-Week Range: $0.34
▼
$1.79

Volume: 801 shs
Average Volume: 15,158 shs
Market Capitalization: $5.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About PainReform (NASDAQ:PRFX) Stock

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

PRFX Stock News Headlines

November 15, 2022 | benzinga.com

PainReform Provides Business Update For Q3 2022; Ended The Quarter With ~$12.9M Cash And Deposits On Hand And No Debt

November 15, 2022 | finanznachrichten.de

PainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2022

November 15, 2022 | finance.yahoo.com

PainReform Provides Business Update for the Third Quarter of 2022

November 8, 2022 | finance.yahoo.com

PainReform Provides Further Update on Manufacturing of PRF-110

October 4, 2022 | finance.yahoo.com

PainReform Provides PRF-110 Manufacturing Update

September 1, 2022 | finance.yahoo.com

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | finance.yahoo.com

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

August 16, 2022 | finance.yahoo.com

PainReform Provides Business Update for the Second Quarter of 2022

July 16, 2022 | uk.finance.yahoo.com

PainReform Ltd. (PRFX)

May 17, 2022 | globenewswire.com

PainReform Provides Business Update for the First Quarter of 2022 - GlobeNewswire

May 17, 2022 | finance.yahoo.com

PainReform Provides Business Update for the First Quarter of 2022 - Yahoo Finance

May 17, 2022 | finance.yahoo.com

PainReform Provides Business Update for the First Quarter of 2022

April 14, 2022 | finance.yahoo.com

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th - Yahoo Finance

April 12, 2022 | globenewswire.com

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th - GlobeNewswire

April 12, 2022 | finance.yahoo.com

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

March 22, 2022 | finance.yahoo.com

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th - Yahoo Finance

March 21, 2022 | globenewswire.com

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th - GlobeNewswire

March 21, 2022 | finance.yahoo.com

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

March 17, 2022 | finance.yahoo.com

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022 - Yahoo Finance

March 17, 2022 | finance.yahoo.com

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

March 8, 2022 | businesswire.com

Global Postoperative Pain Pipeline Market Research Report 2022: Comprehensive Insights about 55+ Companies and 55+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire

January 17, 2022 | benzinga.com

Overview Of Value Stocks In The Healthcare Sector - Benzinga - Benzinga

January 11, 2022 | nasdaq.com

Pre-market Movers: ONE, TSRI, BBLG, AHI, ACCD… - Nasdaq

January 10, 2022 | globenewswire.com

DelveInsight Examines a Robust Pipeline for Postoperative - GlobeNewswire

December 27, 2021 | nasdaq.com

PainReform Ltd Shares Close the Day 13.8% Lower - Daily Wrap

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

PRFX Company Calendar

Last Earnings: 11/15/2021
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/15/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRFX
CUSIP: N/A
CIK: 1801834
Web: www.painreform.com
Phone: 972-9960-1901
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.40
Quick Ratio: 22.99

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.73 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 10,630,000
Free Float: N/A
Market Cap: $5.32 million
Optionable: Not Optionable
Beta: -0.34

Key Executives

Dr. Ehud Geller Ph.D.
Exec. Chairman

Mr. Ilan Hadar M.B.A. (Age 53)
MBA, CEO & CFO

Dr. Sigal Aviel (Age 58)
Chief Operating Officer

Prof. Eli Hazum Ph.D.
CTO & Director

Dr. Stephen A. Cooper D.M.D Ph.D.
Exec. VP of Devel.

Key Competitors

View All Competitors

PRFX Stock - Frequently Asked Questions

How have PRFX shares performed in 2022?: PainReform's stock was trading at $1.33 on January 1st, 2022. Since then, PRFX shares have decreased by 71.0% and is now trading at $0.3862.
View the best growth stocks for 2022 here.
Are investors shorting PainReform?: PainReform saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 400 shares, a drop of 87.9% from the October 31st total of 3,300 shares. Based on an average daily volume of 8,200 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.
View PainReform's Short Interest.
When is PainReform's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our PRFX earnings forecast.
How were PainReform's earnings last quarter?: PainReform Ltd. (NASDAQ:PRFX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.25.

What other stocks do shareholders of PainReform own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).
When did PainReform IPO?: (PRFX) raised $20 million in an initial public offering (IPO) on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.
What is PainReform's stock symbol?: PainReform trades on the NASDAQ under the ticker symbol "PRFX."
How do I buy shares of PainReform?: Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PainReform's stock price today?: One share of PRFX stock can currently be purchased for approximately $0.39.
How much money does PainReform make?: PainReform (NASDAQ:PRFX) has a market capitalization of $4.11 million.
How can I contact PainReform?: The official website for the company is www.painreform.com. The company can be reached via phone at 972-9960-1901 or via email at prfx@crescendo-ir.com.

This page (NASDAQ:PRFX) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial